Myelodysplastic Syndromes and Myeloproliferative Neoplasms


Share

Program Content

Activities

COMMANDS Luspatercept
COMMANDS: Long-term Outcomes of the Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

Provided by

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation